Compare SM & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SM | PBH |
|---|---|---|
| Founded | 1908 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 1992 | 2005 |
| Metric | SM | PBH |
|---|---|---|
| Price | $20.13 | $60.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $37.25 | ★ $86.40 |
| AVG Volume (30 Days) | ★ 3.0M | 461.8K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.33 | 4.04 |
| Revenue | ★ $3,166,673,000.00 | $1,110,479,000.00 |
| Revenue This Year | $32.15 | N/A |
| Revenue Next Year | $35.63 | $2.50 |
| P/E Ratio | ★ $3.18 | $15.05 |
| Revenue Growth | ★ 35.48 | N/A |
| 52 Week Low | $17.58 | $57.25 |
| 52 Week High | $44.95 | $90.04 |
| Indicator | SM | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 53.79 |
| Support Level | $17.71 | $59.19 |
| Resistance Level | $19.80 | $60.65 |
| Average True Range (ATR) | 0.79 | 1.49 |
| MACD | 0.37 | 0.30 |
| Stochastic Oscillator | 77.49 | 81.19 |
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.